Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram or bupropion XL continuation versus placebo with mood stabilizers in bipolar I depression
ISRCTN90111395Phase 3Completed
- Sponsor
- University of British Columbia
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of escitalopram and bupropion in bipolar I disorder and bipolar disorder (BD) (4 arms), sponsored by University of British Columbia. Primary endpoints: Mean improvement in Montgomery-Asberg Depression Rating Scale score from baseline to endpoint, Montgomery-Asberg Depression Rating Scale and 4 more. Started Oct 2009; status: completed.
02
Drugs
escitaloprambupropion
03
Conditions
bipolar I disorderbipolar disorder (BD)
Beyond the preview
Go deeper on ISRCTN90111395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN90111395.